semaglutide cardiovascular risk Weight loss and disease outcomes of semaglutide: a one-year multicentered study soul trial oral semaglutide cardiovascular

GLP-1 medicationsmore commonly known by their brand names such as Ozempic and Wegovy have the potential to reshape the eating and shopping habits of users

For those considering semaglutide, the CMP can reveal underlying issues that might impact treatment safety and effectiveness

The STEP I trial compared semaglutide 2.4mg to placebo for weight reduction in patients without diabetes

Clin Res Hepatol Gastroenterol 2012

GI side effects, anesthesia risk with GLP-1 agonists: what to know

In a 2-year trial, acute pancreatitis was confirmed by adjudication in 8 OZEMPIC-treated patients (0.27 cases per 100 patient years) and 10 placebo-treated patients (0.33 cases per 100 patient years), both on a background of standard of care